PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | ruso |
| Publicado: |
IRBIS LLC
2015-03-01
|
| Colección: | Фармакоэкономика |
| Materias: | |
| Acceso en línea: | https://www.pharmacoeconomics.ru/jour/article/view/37 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|